Molbio Diagnostics, a prominent point-of-care (POC) diagnostics company, has announced a significant collaboration with UE LifeSciences, a Philadelphia-based health technology innovator. This partnership specifically aims to expand access to early breast cancer detection for millions of women across more than 50 developing countries. Indeed, this initiative addresses the critical issue of late diagnosis, which greatly contributes to preventable breast cancer mortality. Furthermore, Molbio Diagnostics will introduce UE LifeSciences’ iBreastExam device across key regions, including India, Africa, the Middle East, CIS countries, the Philippines, Indonesia, and Vietnam.
A New Era for Breast Screening
This exclusive collaboration marks a pivotal step in global women’s health. It strategically combines Molbio’s extensive distribution network with UE LifeSciences’ innovative technology. Consequently, the partnership is set to transform how communities approach breast health screening. The iBreastExam, an FDA-cleared device, offers a radiation-free and painless alternative for breast health screening. This handheld device improves routine clinical breast examinations, helping clinicians identify non-palpable breast lumps in minutes. [12, 13]
The iBreastExam Advantage in Early Breast Cancer Detection
The iBreastExam is a cutting-edge, ultraportable, battery-operated device designed for point-of-care use. It allows screening in primary healthcare settings and during mass public health campaigns. Utilizing advanced sensor technology, the device electronically palpates the breast to identify abnormalities by measuring differences in tissue elasticity. [3, 13] This method standardizes lump detection with minimal training and without requiring user interpretation. [13] Importantly, studies have shown iBreastExam’s potential clinical utility as a pre-screening and triaging tool, aiding in reducing the burden of diagnostic imaging in low- and middle-income countries. It also demonstrates moderate to high diagnostic capacity for malignant lesions, even identifying tumors as small as 0.5 cm. [5, 14]
Addressing Global Disparities in Cancer Care
Mihir Shah, Founder and CEO of UE LifeSciences, emphasized the importance of this collaboration. He stated, “Our collaboration with Molbio Diagnostics is an important step towards improving access to early breast health screening, particularly in areas where access to screening remains a challenge.” [1] Therefore, this partnership directly tackles health inequities by making advanced diagnostic tools available where they are most needed. Molbio’s robust distribution network becomes instrumental in promoting, marketing, selling, and distributing the device to both public and private healthcare providers. [3] This extensive reach ensures that more women can benefit from timely interventions.
Challenges and Opportunities in India
In India, breast cancer screening rates are notably low compared to global standards, largely due to factors such as lack of awareness, social stigma, and limited accessibility. [9] For instance, the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NCDs) in India highlights the importance of information, education, and communication activities for screening success. [2] Experts advocate for policy interventions and mass awareness campaigns to encourage more women to opt for testing. [9] Moreover, clinical breast examinations (CBE) performed by healthcare providers every two years can significantly reduce the stage of breast cancer at diagnosis and improve mortality rates, especially in women aged 50 and above. [7, 10] The iBreastExam, a portable and easy-to-use device, perfectly aligns with the country’s need for accessible and effective early breast cancer detection tools, further supporting national health objectives.
Frequently Asked Questions
Q1: What is the iBreastExam device?
The iBreastExam is a radiation-free, painless, and FDA-cleared breast health screening device developed by UE LifeSciences. It uses advanced sensor technology to detect breast lumps by measuring differences in tissue elasticity, offering a convenient and objective method for early detection. [1, 3, 13]
Q2: Which regions will benefit from this partnership?
Through this collaboration, Molbio Diagnostics will distribute the iBreastExam across India, Africa, the Middle East, CIS countries, the Philippines, Indonesia, and Vietnam, significantly expanding access to early breast cancer detection in these developing regions. [1, 3]
Q3: How does this collaboration address late breast cancer detection?
The partnership aims to overcome barriers to traditional screening methods by providing an accessible, point-of-care device. By leveraging Molbio’s broad distribution network, the iBreastExam can reach millions of women, thereby promoting earlier screening and diagnosis, which is crucial for reducing preventable breast cancer mortality. [1, 3]
References
- Molbio Diagnostics, UE LifeSciences Partner to Expand Access to Early BreastCancer Detection – ETHealthworld
- Breast cancer screening initiative in India – an update | The BMJ
- Molbio Diagnostics collaborates with UE LifeSciences to expand iBreastExam to the global market – Pharmabiz.com
- Molbio announces collaboration with UE LifeSciences to expand iBreastExam globally
- Can the Clinical Utility of iBreastExam, a Novel Device, Aid in Optimizing Breast Cancer Diagnosis? A Systematic Review – PubMed
- Challenges and Innovations in Breast Cancer Screening in India: A Review of Epidemiological Trends and Diagnostic Strategies
- Policy push needed to boost breast cancer screening among women: Experts | Health News
- Strategies to reduce breast cancer burden in India: Prevention and early diagnosis hold the key – Karkinos Healthcare
- Emerging Breast Cancer Screening Tool to See Wider Distribution in U.S. – Diagnostic Imaging
- iBreastExam – UE LifeSciences
- Can the Clinical Utility of iBreastExam, a Novel Device, Aid in Optimizing Breast Cancer Diagnosis? A Systematic Review | JCO Global Oncology – ASCO Publications
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.